AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19764973 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal maximum voided volume
Number of subjects: 43
Study 19764973 — intervention group
Group type: EXPERIMENTAL
Intervention: Small maximum voided volumes
Number of subjects: 43
Study 19764973 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal polyuria
Number of subjects: 43
Study 19764973 — intervention group
Group type: EXPERIMENTAL
Intervention: Without nocturnal polyuria
Number of subjects: 43
Study 19764973 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse in group A
Number of subjects: 43
Study 18360660 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + PDT (one time)
Number of subjects: 58
Study 18360660 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + PDT (two times)
Number of subjects: 58
Study 18360660 — intervention group
Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 58
Study 16202531 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg S(+)‐ketamine
Number of subjects: 33
Study 16202531 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg S(+)‐ketamine
Number of subjects: 33
Study 16202531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 12952549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean type diet (MD group)
Number of subjects: 51
Study 12952549 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD group)
Number of subjects: 51
Study 12952549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MD and CD groups
Number of subjects: 51
Study 10658526 — intervention group
Group type: EXPERIMENTAL
Intervention: BFM protocol
Number of subjects: 57
Study 10658526 — intervention group
Group type: COMPARATOR
Intervention: MB protocol
Number of subjects: 57
Study 9118580 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteriorly placed ventilation tubes
Number of subjects: 121
Study 9118580 — intervention group
Group type: COMPARATOR
Intervention: Posteriorly placed ventilation tubes
Number of subjects: 121
Study 10149618 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated implants
Number of subjects: 0
Study 10149618 — intervention group
Group type: COMPARATOR
Intervention: Uncoated implants
Number of subjects: 0
Study 6130379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release fenfluramine
Number of subjects: 42
Study 6130379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 28532259 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive intervention (20-minute session with therapist providing psychoeducation and personalized feedback)
Number of subjects: 0
Study 28532259 — intervention group
Group type: COMPARATOR
Intervention: Cultural values intervention (20-minute session with therapist)
Number of subjects: 0
Study 28532259 — intervention group
Group type: COMPARATOR
Intervention: Non-directive intervention (20-minute session with therapist providing psychoeducation and personalized feedback)
Number of subjects: 0
Study 28723812 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (linear periodized program)
Number of subjects: 16
Study 28723812 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (daily undulating periodized program)
Number of subjects: 16
Study 28723812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 26888911 — intervention group
Group type: EXPERIMENTAL
Intervention: ART for 48 weeks in CHI
Number of subjects: 52
Study 26888911 — intervention group
Group type: EXPERIMENTAL
Intervention: ART for 48 weeks in PHI
Number of subjects: 52
Study 24526542 — intervention group
Group type: EXPERIMENTAL
Intervention: CSD skills training (lectures, deliberate practice, and self-study)
Number of subjects: 56
Study 24526542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 56
Study 22067724 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone for 6 months
Number of subjects: 99
Study 22067724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 20518934 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 17
Study 20518934 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 17
Study 18041081 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg AZLI administered BID for 14 days
Number of subjects: 105
Study 18041081 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg AZLI administered BID for 14 days
Number of subjects: 105
Study 18041081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 15921379 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim-mobilized peripheral blood progenitor cells (PBPC)
Number of subjects: 350
Study 15921379 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 350
Study 12898882 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological examination after surgical treatment
Number of subjects: 38
Study 12898882 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological examination
Number of subjects: 38
Study 10575073 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected walking speed
Number of subjects: 27
Study 10575073 — intervention group
Group type: COMPARATOR
Intervention: Slow walking speed (60% of self-selected)
Number of subjects: 27
Study 9019842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMH) in a single daily dose of 25000 U
Number of subjects: 99
Study 9019842 — intervention group
Group type: COMPARATOR
Intervention: Non-fractionated heparin (NFH) in twice daily dose of 12500 U
Number of subjects: 99
Study 9019842 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of low-molecular-weight heparin (LFH)
Number of subjects: 99
Study 1874236 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement (160 mg daily)
Number of subjects: 28
Study 1874236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6753454 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective HLA‐A and ‐B matching
Number of subjects: 159
Study 29471861 — intervention group
Group type: EXPERIMENTAL
Intervention: FITNET-NHS (online CBT)
Number of subjects: 734
Study 29471861 — intervention group
Group type: COMPARATOR
Intervention: Activity Management (delivered via video call)
Number of subjects: 734
Study 29471861 — intervention group
Group type: EXPERIMENTAL
Intervention: FITNET-NHS
Number of subjects: 734
Study 27842564 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel prevention boot
Number of subjects: 183
Study 24717370 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA-rich diet (17:11:4; n = 65)
Number of subjects: 195
Study 24717370 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (9:19:4; n = 64)
Number of subjects: 195
Study 24717370 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 PUFA-rich diet (9:13:10; n = 66)
Number of subjects: 195
Study 24717370 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 195
Study 22505702 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 444
Study 22505702 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX
Number of subjects: 444
Study 22505702 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + placebo
Number of subjects: 444
Study 22505702 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 444
Study 20943111 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC therapy (10 days pre-treatment with VAC dressings)
Number of subjects: 100
Study 20943111 — intervention group
Group type: COMPARATOR
Intervention: Normal saline gauzes (control group)
Number of subjects: 100
Study 20943111 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC therapy
Number of subjects: 100
Study 18439502 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cervical anesthesia
Number of subjects: 82
Study 18439502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cervical and intrauterine anesthesia
Number of subjects: 82
Study 16419567 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual evoked potentials (VEP) in patients with migraine
Number of subjects: 90
Study 16419567 — intervention group
Group type: COMPARATOR
Intervention: Visual evoked potentials (VEP) in patients with tension-type headache (TTH)
Number of subjects: 90
Study 16419567 — intervention group
Group type: COMPARATOR
Intervention: Visual evoked potentials (VEP) in healthy control group
Number of subjects: 90
Study 12907892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal mini micrometastases detected by immunohistochemical staining
Number of subjects: 399
Study 12907892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear and histologic grades
Number of subjects: 399
Study 10494522 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Bandaging (CB)
Number of subjects: 38
Study 10494522 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Bandaging + Manual Lymph Drainage (CB + MLD)
Number of subjects: 38
Study 8724706 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 20
Study 8724706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride (CPC)
Number of subjects: 20
Study 8724706 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan
Number of subjects: 20
Study 8724706 — intervention group
Group type: EXPERIMENTAL
Intervention: C31G
Number of subjects: 20
Study 8724706 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 1931406 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% isoflurane in oxygen
Number of subjects: 40
Study 1931406 — intervention group
Group type: COMPARATOR
Intervention: 2% isoflurane and nitrous oxide in oxygen
Number of subjects: 40
Study 6802937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (1.4 gm/kg)
Number of subjects: 22
Study 6802937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol plus furosemide (0.3 mg/kg)
Number of subjects: 22
Study 31985629 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf-length sequential compression devices
Number of subjects: 50
Study 31985629 — intervention group
Group type: COMPARATOR
Intervention: No sequential compression devices
Number of subjects: 50
Study 30778715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncology nurse phone calls (AMA)
Number of subjects: 60
Study 30778715 — intervention group
Group type: COMPARATOR
Intervention: Non-AMA (control group)
Number of subjects: 60
Study 30778715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncology nurse interventions (AMA)
Number of subjects: 60
Study 30778715 — intervention group
Group type: EXPERIMENTAL
Intervention: RDI < 80%
Number of subjects: 60
Study 30365588 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg SC twice weekly for 12 weeks, then 50 mg SC once weekly for an additional 12 weeks
Number of subjects: 80
Study 25842991 — intervention group
Group type: COMPARATOR
Intervention: Dorsal slit incision technique (Group A)
Number of subjects: 60
Study 25842991 — intervention group
Group type: EXPERIMENTAL
Intervention: Double incision (sleeve) technique (Group B)
Number of subjects: 60
Study 23998556 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended assisted ventilation (EAV)
Number of subjects: 283
Study 23998556 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment regime
Number of subjects: 283
Study 21865366 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T(3)
Number of subjects: 14
Study 21865366 — intervention group
Group type: COMPARATOR
Intervention: L-T(4)
Number of subjects: 14
Study 19903335 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study 19903335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16932963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ICS plus long-acting beta2 agonist)
Number of subjects: 43
Study 16932963 — intervention group
Group type: COMPARATOR
Intervention: Single ICS
Number of subjects: 43
Study 14665875 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 core transperineal biopsy
Number of subjects: 214
Study 14665875 — intervention group
Group type: COMPARATOR
Intervention: 6 core transperineal biopsy
Number of subjects: 214
Study 11524643 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors (various studies)
Number of subjects: 4
Study 11524643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin (PRISM-PLUS study)
Number of subjects: 4
Study 11524643 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrilin therapy (PURSUIT trial)
Number of subjects: 4
Study 11524643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban alone (PRISM-PLUS study)
Number of subjects: 4
Study 11524643 — intervention group
Group type: EXPERIMENTAL
Intervention: Least harmful treatment arm (GUSTO‐IV trial)
Number of subjects: 4
Study 11524643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined studies using a random effects model
Number of subjects: 4
Study 9458423 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsidomine (1 mg.h‐1 on average)
Number of subjects: 568
Study 9458423 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (2.5 mg.h‐1 on average)
Number of subjects: 568
Study 7557370 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 35
Study 7557370 — intervention group
Group type: COMPARATOR
Intervention: X-ray
Number of subjects: 35
Study 7557370 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible rhinoscopy
Number of subjects: 35
Study 7557370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal smears for polymorphonuclear cells and eosinophils
Number of subjects: 35
Study 7557370 — intervention group
Group type: EXPERIMENTAL
Intervention: Other laboratory tests (CBC, sedimentation rate, quantitative immunoglobulins, total IgEs)
Number of subjects: 35
Study 2693029 — intervention group
Group type: EXPERIMENTAL
Intervention: porcine glucose-dependent insulinotropic polypeptide (GIP) (0.75 pmol/kg/min)
Number of subjects: 6
Study 2693029 — intervention group
Group type: COMPARATOR
Intervention: control solution (CS)
Number of subjects: 6
Study 793286 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 14
Study 793286 — intervention group
Group type: COMPARATOR
Intervention: methohexitone
Number of subjects: 14
Study 793286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 14
Study 31175096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to cisplatin and pemetrexed (PCB)
Number of subjects: 448
Study 31175096 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus pemetrexed (PC)
Number of subjects: 448
Study 26046499 — intervention group
Group type: EXPERIMENTAL
Intervention: VR rehabilitation plus conventional OT
Number of subjects: 35
Study 26046499 — intervention group
Group type: COMPARATOR
Intervention: Conventional OT alone
Number of subjects: 35
Study 22751218 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse and diagonal pelvic belt configurations (50 N force)
Number of subjects: 20
Study 21484033 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage
Number of subjects: 10
Study 21484033 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 10
Study 19083444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (low-CHO)
Number of subjects: 28
Study 19083444 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 28
Study 16413056 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human interleukin 11 (rhIL-11) at 50 microg/kg/day and granulocyte-macrophage colony stimulating factor (GM-CSF) at 250 microg/kg/day administered from day 11 until recovery.
Number of subjects: 34
Study 16413056 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human interleukin 11 (rhIL-11) and GM-CSF as supportive care after chemotherapy.
Number of subjects: 34
Study 12831635 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin antibodies levels after severe hypoglycemia
Number of subjects: 33
Study 12831635 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin antibodies levels before severe hypoglycemia
Number of subjects: 33
Study 12831635 — intervention group
Group type: COMPARATOR
Intervention: Control group insulin antibodies levels
Number of subjects: 33
Study 12831635 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IA levels before and after severe hypoglycemia
Number of subjects: 33
Study 10832727 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm group (n = 11)
Number of subjects: 19
Study 10832727 — intervention group
Group type: COMPARATOR
Intervention: Full-term group (n = 8)
Number of subjects: 19
Study 8638169 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy at specific stages of progression of retinopathy
Number of subjects: 0
Study 1630657 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg orally, t.i.d. for 7 consecutive days)
Number of subjects: 7
Study 6149490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol chloride infusion (0.05 to 0.7 mg/day)
Number of subjects: 4
Study 6149490 — intervention group
Group type: COMPARATOR
Intervention: Single‐blind saline placebo infusions
Number of subjects: 4
Study 30696270 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted ICBT for at-risk patients (N=51)
Number of subjects: 251
Study 30696270 — intervention group
Group type: COMPARATOR
Intervention: Standard ICBT for at-risk patients (N=51)
Number of subjects: 251
Study 30696270 — intervention group
Group type: COMPARATOR
Intervention: Not at risk patients (N=149)
Number of subjects: 251
Study 30696270 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted ICBT for at-risk patients
Number of subjects: 251
Study 29029797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol
Number of subjects: 300
Study 29029797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 300
Study 29029797 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 300
Study 27887601 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulations (0.5Hz‐5Hz, bipolar, square wave, pulse width 1 ms) applied using a custom‐made transurethral catheter at different locations of the lower urinary tract
Number of subjects: 90
Study 27887601 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulations at different locations of the lower urinary tract
Number of subjects: 90
Study 24212061 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention practices using academic detailing
Number of subjects: 66
Study 24212061 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention practices
Number of subjects: 66
Study 23705345 — intervention group
Group type: EXPERIMENTAL
Intervention: Group songwriting session
Number of subjects: 99
Study 23705345 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 99
Study 21055588 — intervention group
Group type: EXPERIMENTAL
Intervention: En-masse retraction
Number of subjects: 64
Study 21055588 — intervention group
Group type: COMPARATOR
Intervention: 2-step retraction
Number of subjects: 64
Study 21055588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups pooled
Number of subjects: 64
Study 21055588 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 64
Study 21055588 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adolescents
Number of subjects: 64
Study 17991659 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (30 mg/d for 8 weeks)
Number of subjects: 71
Study 17991659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 15769499 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual presentation mode
Number of subjects: 64
Study 15769499 — intervention group
Group type: COMPARATOR
Intervention: Audio-only presentation mode
Number of subjects: 64
Study 15769499 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing frequency of stuttering
Number of subjects: 64
Study 15769499 — intervention group
Group type: EXPERIMENTAL
Intervention: Five theme clusters of comments
Number of subjects: 64
Study 12489064 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 22.9% of energy from saturated fat
Number of subjects: 32
Study 12489064 — intervention group
Group type: COMPARATOR
Intervention: Diet with 9.3% of energy from saturated fat replaced by trans fat
Number of subjects: 32
Study 9624555 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin
Number of subjects: 55
Study 9624555 — intervention group
Group type: EXPERIMENTAL
Intervention: ofloxacin
Number of subjects: 55
Study 9624555 — intervention group
Group type: EXPERIMENTAL
Intervention: minocycline
Number of subjects: 55
Study 9624555 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin
Number of subjects: 55
Study 9624555 — intervention group
Group type: EXPERIMENTAL
Intervention: cefotiam
Number of subjects: 55
Study 7714306 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 44
Study 7714306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 44
Study 7714306 — intervention group
Group type: COMPARATOR
Intervention: Nonresponse
Number of subjects: 44
Study 2109432 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactinex (culture of L. acidophilus and L. bulgaricus), administered four times a day for ten days
Number of subjects: 0
Study 2109432 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered four times a day for ten days
Number of subjects: 0
Study 390810 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate (Estracyt)
Number of subjects: 107
Study 31847572 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing normal weight individuals engaging in vigorous exercise
Number of subjects: 102
Study 31847572 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing overweight/obese individuals engaging in vigorous exercise
Number of subjects: 102
Study 31847572 — intervention group
Group type: COMPARATOR
Intervention: No-exercise video with participants of various weight statuses (control condition)
Number of subjects: 102
Study 31161722 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program based on Roy's adaptation model for 4 weeks
Number of subjects: 76